Time to surgery after neoadjuvant chemotherapy in breast cancer and its impact on survival in a middle-income country.

e12640 Background: The time to surgery after neoadjuvant chemotherapy (NACT) in breast cancer and its impact on survival has not been sufficiently evaluated in low- or middle-income countries. The objective of this study was to analyze the impact on overall survival in a cancer hospital in Guayaquil, Ecuador. Methods: This is a retrospective study carried out at the SOLCA Guayaquil Hospital in Ecuador from January 2009 to December 2011. The inclusion criteria were women ≥18 years old, diagnosed with invasive breast cancer in stages II and III, who were treated with NACT followed by surgery. The data were collected from clinical records; those with incomplete data were excluded, and the variables age, stage, lymphovascular invasion (LVI), and pathological response were included. Survival was grouped into 50 years), HR: 1.69 p=0.011; were factors that statistically contributed to worse survival, however, the time between the end of NACT and surgery < 8 and ≥ 8 weeks (p = 0.07) had no statistical impact on survival. Nonetheless, a numerical trend towards better survival was noted in the < 8 week group. Conclusions: The delay in time to surgery after NACT had a negative trend in survival, although it was not statistically significant, which may be due to the small sample size. Table: see text